Clinical importance of microalbuminuria in diabetes and hypertension

Current Hypertension Reports

Volumn 6, Issue 5, 2004, Pages 352-356

  Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CALCIUM ANTAGONIST; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; METOPROLOL; PLACEBO; RAMIPRIL; SODIUM; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART PROTECTION; HUMAN; HYPERTENSION; MICROALBUMINURIA; PRACTICE GUIDELINE; PROTEIN URINE LEVEL; SODIUM INTAKE;

EID: 5444227233     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0053-1     Document Type: Article

References (37)

1. Eknoyan G, Hostetter T, Bakris GL, et al.: Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003, 42: 617-622.
2. Abosaif NY, Arije A, Atray NK, et al.: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43: 1-290.
3. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7: 35-43.
4. Langham RG, Kelly DJ, Cox AJ, et al.: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002, 45: 1572-1576.
5. Cooper ME, Mundel P, Boner G: Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 2002, 22: 393-398.
6. Clausen P, Jensen JS, Jensen G, et al.: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001, 103: 1869-1874.
7. Stuveling EM, Bakker SJ, Hillege HL, et al.: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004, 43: 791-796.
8. Stuveling EM, Hillege HL, Bakker SJ, et al.: C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis 2004, 172: 107-114.
9. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59: 260-269.
10. Takeda T, Hoshida S, Nishino M, et al.: Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003, 169: 155-158.
11. Di NM, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003, 34: 2922-2929.
12. Wachtell K, Ibsen H, Olsen MH, et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003, 139: 901-906.
13. Turnbull F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362: 1527-1535.
14. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2): B54-B64.
15. Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288: 2421-2431.
16. The Diabetes Control and Complications Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 1995, 47: 1703-1720.
17. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy, and strokes. Kidney Int 2002, 61: 1086-1097.
18. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355: 253-259.
19. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317: 703-713.
20. Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321: 412-419.
21. Adler AI, Stevens RJ, Manley SE, et al.: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63: 225-232.
22. Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134: 629-636.
23. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345: 870-878.
24. Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334: 939-945.
25. Summary of Revisions for the 2004 Clinical Practice Recommendations. Diabetes Care 2004, 27: S1-S146.
26. Ruggenenti P, Perna A, Gherardi G, et al.: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000, 35: 1155-1165.
27. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361: 117-124.
28. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14: 992-999.
29. Bakris GL, Weir MR: Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens 1996, 9: 200S-206S.
30. Sica DA: What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure? Blood Press Monit 1999, 4(Suppl 2): S9-S16.
31. Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65: 1991-2002.
32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290: 2805-2816.
33. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345: 851-860.
34. Griffin KA, Picken MM, Bakris GL, Bidani AK: Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999, 55: 1849-1860.
35. Griffin KA, Hacioglu R, bu-Amarah I, et al.: Effects of calcium channel blockers on "dynamic" and " steady-state step" renal autoregulation. Am J Physiol Renal Physiol 2004, 286: F1136-F1143.
36. Bakris GL, Weir MR, Shanifar S, et al.: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003, 163: 1555-1565.
37. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42: 1206-1252.